The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210000, China
NCT Number: NCT04376008
This trial aims to prospectively assess the feasibility, complications and functional results of free-hand transperineal image fusion targeted biopsies under local anesthesia in a large group of patients.
Looking for future studies?
Notify Me18 year–80 year
Male
Interventional
Not applicable
Nanjing, Jiangsu, 210000, China
12-core transrectal ultrasound (TRUS) biopsy is one of the most performed urological procedures and remains the standard method for prostate cancer (PCa) histological diagnosis according to the most recent Guidelines. During the last decade, the transperineal prostate biopsy has attracted renewed interest. However, only a few studies and no large prospective studies investigated complications of the transperineal approaches.
Image fusion of Multi-parameter MRI (mpMRI) and TRUS guided prostate targeted biopsy had equivalent results with standard 12-core biopsy. Combination of targeted and standard biopsy was recommended in recent Guidelines. Image fusion targeted biopsy needs satisfactory anesthetic effect, and no prospective studies investigated feasibility in this approach under local anesthesia.
The scientific urological community is focusing on detection rate and concordance with final pathology of the radical prostatectomy specimen, which remain the cornerstones to assess the accuracy of a prostate biopsy technique. In this study, the investigators will additionally assess the functional results of erectile function and urinary function.
Together, the investigators will perform free-hand image fusion targeted biopsies plus standard biopsies under local anesthesia in patients recruited in this study. Then, Feasibility, such as peri-procedural pain, changes in patients quality of life; complications, such as infection rate and bleeding rate; functional results, such as erectile function and urinary function; and concordance with final pathology will be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Transperineal TRUS guided standard prostate biopsy (SB).
Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
Time frame: 1 days
The proportion of patients who failed to complete the biopsy due to various reasons during the biopsy
Time frame: 3 days peri-biopsy
Numerical pain scale score during biopsy, the minimum to maximum value is 0 to 10, and higher scores mean a worse outcome
Time frame: 7 days post biopsy
The proportion of subjects requiring hospitalization for various reasons within 7 days after puncture
Time frame: 30 days post biopsy
Clinically significant prostate cancer is considered as: biopsy Gleason score ≥3+4 or maximum cancer core length ≥5 mm.
Time frame: 30 days post biopsy
Prostate cancer is considered as: biopsy Gleason score ≥3+3
Time frame: 30 days post biopsy
Time frame: 1 days
How much time is used during biopsy
Time frame: 30 days post biopsy
Concordance rate between biopsy and final pathology
Time frame: 30 days post biopsy
pre- and post-procedural erectile function score, the minimum to maximum value is 0 to 25, and higher scores mean a better outcome
Time frame: 30 days post biopsy
pre- and post-procedural urinary function score, the minimum to maximum value is 0 to 35, and higher scores mean a worse outcome
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Other
Evaluation of Feasibility, Complications And Functional Results Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia: A Prospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04019327
Castration-resistant Prostate Cancer, Genital Diseases
Basking Ridge, New Jersey, United States
View Trial DetailsNCT03493945
Advanced Solid Tumor, Genital Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03344757
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Miami, Florida, United States
View Trial DetailsNCT05137561
Genital Diseases, Genital Diseases, Male
Chandigarh, India
View Trial Details